Veterinary Medicines Legislation Update

Caroline Garvan
Veterinary Inspector

APHA Animal Health Conference
4th September 2012



Veterinary Medicines Package

- Review of Directive 2001/81- approval,
 distribution, prescribing & use of vet. Medicines
- Review of Directive 90/167 manufacture, distribution, prescribing and use of medicated feed





Directive 2001/82

Comprehensive review in 2003/2004

- Ongoing Problems identified:
 - → Variation in availability in MS
 - → Operation of Single market
 - → Administration Burdens



Availability of Veterinary Medicines

- Smaller countries ↓ no. of authorised medicines
- Few authorised medicines for minor species
- Few authorised medicines for some therapeutic categories
- Innovation low no. of new MA, insufficent data protection



Single Market

Majority of MA holders only have MA in single national market

Administration Burdens

Costs of Regulatory Requirements:

EUR 538 million / year → 13% of turnover



- -91 million-cost of applying for MA
- -184 million-packaging & labelling,
- 262 million existing MAs

Objectives for Revision

- Improve functioning of single market
- ↑ level of protection of human & animal health
- 1 availability of veterinary medicines
- ¬ administration burden
- Improved response to AMR



Direction of Commission Review

- Commission proposals -2013
- Policy options for discussion:
- → Authorisation procedure-Coalition of IFAH-Europe, FVE, EGGVP, COPA-COGECA — 1-1-1 Other stakeholders — 2 authorisation routes and European-wide binding
- → Data Protection Industry 8 years for new products, +3 for each additional species, max 20



Marine - Other stakeholders 13 years for major species, 15 for minor species

Direction of Commission Review

- Packaging & Labelling simplify requirements
- Pharmacovigilance and monitoiring simplify requirements, risk based approach
- Off-label use
- Harmonisation of already authorised products
- Antimicrobial resistance



Directive 90/167

- Last reformed 1990 outdated
- Mainly pig and poultry sectors

• Expect more specific & restrictive control

provisions






Production & Use of medicated feed in EU

- Size of market varies between Member States
- No. of authorised premixes varies
- Importance of medicated feed compared to oral administration is reduced
- Cost of mixing medicated feed is higher if production levels low & technology requires investment



IMB Data

Breakdown of Veterinary antimicrobial substances used in 2010 in Ireland.




- → public health priority
- → 25,000 deaths in EU annually WHO
- AMR → EUR 1.5 BILLION (lost productivity, healthcare)
 - → 4 million patients/year acquiring a healthcare associated infection



It was on a short-cut through the hospital kitchens that Albert was first approached by a member of the Antibiotic Resistance.



Antimicrobial Resistance L Human Animal





European Parliament Resolutions


- Prudent use of antimicrobials- maintain efficacy in humans & animals
- Importance of Monitoring & surveillance of AMR system- EFSA/ECDC
 ESVAC/ EARS-Net & ESAC-NET
- Continued research & development of new antimicrobials, alternatives – vaccines
- Holisitic approach-disease prevention,
 improved husbandry

Commission Action Plan

- Actions to date:
- 2006 ban on use of AM for growth promotion
- Monitoring zoonotic AMR and use of antimicrobials
- International activities TATFAR, WHO, OIE
 CODEX
- Research-scientific opinions



Commission Action Plan





12 Concrete Actions – Key points

- (1)Promotion of appropriate use of AMs CIAs 3rd & 4TH gen. cephalosporins, flouroquinolones
- ↓ in overall usage- use only when necessary CVMP
- (2) Strengthen Regulatory Framework- review
- appropriate warnings on labels
- Restrictions on regular or off-label use of new or CIAs for humans in veterinary sector



12 Concrete Actions – Key points

- (2) Strengthen Regulatory Framework→ Review
- Amending rules for advertising
- Revisit authorisation requirements to address risks and benefits of antimicrobials
- (3) Recommendations for veterinary use
- (5) New Animal Health Law to focus on disease prevention




12 Concrete Actions – Key points

- (7) Research & incentives for development of new Veterinary antimicrobial
- (10) Strengthen surveillance of AMR & monitoring of consumption- Animal Health law AMR in animal disease, Harmonised data between MS, Harmonised between human & veterinary
- International cooperation, communication &



Council Conclusions

- Calls on MS to develop strategy to address AMR
- Guidelines on treatment-prudent use
- Clinical sampling & diagnostic tests
- legislation preventing illegal sales
- Limit use of CIAs
- Limit prophylactic use
- Herd usage justified by vet



Council Conclusions

- Effective surveillance system to allow comparison
- Collection of data on sale & use of antimicrobials in animals
- Intersectoral coordination to monitor implementation of national strategy
- Co-ordinated action at international level
- Training & Education



Denmark: 1995 Danmap, Vetstat
 1994-2011 ↑ pig production 50%, ↓ AM 47%
 Risk Management- monitoring usage & AMR

- → need for AM-vaccination, yellow card system
- Prudent use- Vetprax-vet usage
- -Decoupling prescribing & supply
- Treatment guidelines
- Herd health agreement



- Denmark –
- 2002 restrictions on fluoroquinolones
- 1 therapeutic usage until 2009
- 2010 non voluntary herd health agreement cattle & pigs
- Establishment of threshold values for herd levels AM usage & mortality

- Netherlands: 1999 Nethmap
 2006 AGP ban but therapeutic use ↑-usage static
 MRSA PUBLIC HEALTH ISSUE
 Target 50% ↓ in 3 years by 2013
 - Guidelines to limit prescribing of CIAs
- Germany: Therapeutic use only
 - Legislative changes for vets
 - diagnostic tests- antibiogram
 - Cascade not permitted for CIAs



France: 1999 ANSES

Antibiotic Usage 个 28% 1999-2009

Target: 25% in 5 years

Strategy – promotion of good practice, awareness

Development of alternatives to AM usage

Re-inforce controls

Consolidation of monitoring system

Promotion of European approach& international



actitivities

Resistance Stats – NRL 2011

- Salmonella spp. 78% resistance (DT104 98%)
 (500 SAMPLES) Highest in pigs and cattle
 -5% resistance fluoroquinolones
 Poultry resistance highest to CIAs
- Campylobacter spp poultry
 C. jejuni 64.7%

 - C. coli 59% 40% resistance to flouroquinolones $15\% 2008 \rightarrow 57\% 2010$



Resistance Stats – NRL 2011

- Commensal E. coli & Enterococcus spp.
- Indicators of selective pressure that spread horizontally to zoonotic or other bacteria thru food chain or environment

E. coli (poultry) - 85% resistant to 1 ab, 40% 5 +

50% resistant to amp, oxytet, sulp

Enterococcus spp. poultry resistance levels varied

80% tetracyclines

68% erythromycin

0.07% vancomycin



EFSA & ECDC Joint Report

- Occurrence of resistance in animals & food remained similar to previous years
- Humans- campylobacter (200,000 cases)
- high resistance to ciprofloxacin, ampicillin & teracyclines
- Salmonellosis 100,000 cases 2012, low resistance to CIAs
- Direct comparison between resistance findings in humans & animals cannot be made as different definition for resistance- harmonisation required

^{An Roinn} Talmhaíochta, Bia agus Mara





Healthy Animals → **Premium Food**

- Agri-food Exports € 8.85 billion (12% ↑ 2011)
 25% of rise in total export revenue
- Export orientated industry □ Improved Market Access
 & Volume Growth (25% ↑ exports)
- Food Harvest 2020Target: Txports to 11.16 bill(42%)



To Conclude

 '..the current review provides a massive opportunity – an opportunity for all to engage in a fundamental rethink of the whole system of veterinary medicines ..It is an opportunity to re-mould the model; to modernise and to improve it." Commissioner Dalli



Thank you for your attention!

